Compare Lumen Technologies Inc (LUMN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs TG Therapeutics Inc — how do they compare? Lumen Technologies Inc trades at $5.28 (market cap $5.73B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and TG Therapeutics Inc for 16 Days on average.
| LUMN | TGTX | |
|---|---|---|
Market Cap | $5.73B | $8.16B |
Volume | 17,079,799 | 1,735,121 |
Sector | Media | Health |
52-Week High | $11.83 | $59.06 |
52-Week Low | $5.53 | $26.94 |
Typical Hold Time | 40 Days | 16 Days |
Enterprise Value | $17.35B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $5.56, down 5.92% on the day, reflecting ongoing investor caution amid weak profitability and high debt. The stock shows a bearish technical trend with key support at $5.00, while fundamentals reveal declining revenue, negative net income margins, and a challenging turnaround effort. Recent news highlights a Nasdaq listing move and AI-focused networking initiatives, but legacy telecom declines persist.
Outlook remains speculative with high execution risk; the company's deep value (P/S 0.47) and AI growth potential contrast with consistent losses and substantial leverage. Analyst consensus is Reduce, with 60.7% Hold ratings, signaling limited near-term confidence despite strategic pivots.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
